BD (NYSE:BDX) announced today that it increased its manufacturing capacity and domestic supply for syringes and needles. Franklin Lakes, N.J.-based BD’s new syringe and needle manufacturing lines, which were completed on an accelerated timeline, represent BD’s partnership with Department of Health and Human Services’ (HHS) Assistant Secretary for Preparedness and Response (ASPR). In July 2020, […]
COVID-19
BD says glass prefillable syringes still perform after deep cold storage
BD (NYSE:BDX) today shared the results from a preliminary study investigating the impact of deep cold storage on glass prefillable syringes. Franklin Lakes, N.J.-based BD’s study evaluated deep cold storage (-20°C and -40°C) as traditional vaccine formulations are commonly stored up to about 2°C to 8°C, while mRNA vaccine formulations (the type of COVID-19 vaccine […]
Scancell picks PharmaJet’s needle-free injection systems to deliver COVID-19 vaccine candidates
PharmaJet announced today that its partner, Scancell, chose its needle-free injection platform to administer its COVID-19 vaccine candidates. Scancell selected Golden, Colorado-based PharmaJet’s devices to administer two SARS-CoV-2 DNA-based vaccine candidates, SCOV1 and SCOV2. The vaccines will be exclusively administered using the PharmaJet Tropis and PharmaJet Stratis needle-free injection systems. According to a news release, […]
Overcoming vaccine delivery device design’s top challenges
Vaccine delivery has long been a hot topic and only got hotter in the ongoing push to vaccinate against COVID-19 around the world. Most would probably associate vaccines with the standard “jab” injection with a syringe. Over the past year and more, companies have touted ideas for other avenues. Inovio has a “smart” delivery device […]
Three companies to collaborate on potential inhaled COVID-19 treatment
Signal Rx Pharmaceuticals, Crystec and ADYA are working on a dry powder drug formulation for potentially treating COVID-19-related illness. The three companies’ collaboration for the dry powder formulation of SF2523 covers the treatment of pulmonary fibrosis, lung cancer and illnesses related to SARS-CoV-2, the virus causing COVID-19. SignalRx’s SF2523 is a novel, small-molecule, dual PI3K-BRD4 […]
Vaxart stock soars after FDA approves IND application for oral COVID-19 vaccine tablet
Vaxart (NSDQ:VXRT) announced today that the FDA cleared the investigational new drug (IND) application for its oral COVID-19 vaccine. Upon news of the IND application approval for the S-only protein construct-based vaccine candidate, shares of VXRT were up 16.1% at $8.35 in early-morning trading today. South San Francisco-based Vaxart’s S+N oral tablet SARS-CoV-2 vaccine candidate […]
Teva dips before hours on Q2 revenue miss, lowered guidance
Teva Pharmaceuticals (NYSE:TEVA) shares took a hit this morning on second-quarter revenues that missed the consensus forecast. The Tel Aviv, Israel-based company posted profits of $207 million, or 19¢ per share, on sales of $3.9 billion for the three months ended June 30, 2021, for a 47.9% bottom-line gain on sales growth of 1%. Adjusted […]
PharmaJet begins enrollment for needle-free COVID-19 vaccine trial
PharmaJet announced today that it began enrollment for a Phase 1 clinical trial for its needle-free COVID-19 vaccine in Australia. Golden, Colo.-based PharmaJet’s needle-free injection systems will be studied with Covigen, a DNA-based vaccine developed by French-Thai pharmaceutical company BioNet-Asia in collaboration with Melbourne, Australia-based Technovalia. According to a news release, PharmaJet’s system was chosen […]
BD surpasses 2 billion orders for COVID-19 vaccine injection devices
BD (NYSE:BDX) announced today that orders for its needles and syringes hit 2 billion amid global COVID-19 vaccination efforts. Franklin Lakes, N.J.-based BD’s latest milestone comes less than six months after the company surpassed 1 million orders for vaccine delivery devices. The order total encompasses commitments to governments all over the globe, including the U.S., […]
NRx Pharmaceuticals touts Zyesami results, seeks EUA for treating COVID-19
NRx Pharmaceuticals (NSDQ:NRXP) announced that it applied for FDA emergency use authorization based on a study of its Zyesami therapeutic. Radnor, Pa.-based NRx Pharmaceuticals, formerly NeuroRx, just last week completed a merger with SPAC Big Rock Partners Acquisition Corp. and went public, changing its name in the process. The company develops Zyesami, a synthetic form […]
